Monday, April 20, 2015 2:34:24 PM
As the smart money reads the tea leaves (publicly available data on MNTA's FDA application/ data from the extensive legal record/ the steep wall faced by other generic copaxone applications), I think it inevitable that they will see this stock as tremendously undervalued. It won't remain that way.
The immediate post-approval 'pop' was understandably undercut by disappointed longs running for the exits -- but will still going to occur. A fresh look by smart eyes will lift this stock much higher.
MNTA's debacle following the Lovenox approval is one that they've learned from. This is a different product. Sometimes the past doesn't even rhyme with the future.
Cheers,
MTB
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM